Tebipenem

Class: Beta-lactam

Spectrum of activity:	Gram-negative
Details of activity:	UTI pathogens.
Institute where first reported:	Spero Therapeutics
Year first mentioned:	2009
Highest developmental phase:	Phase 3
Development status:	Active

Chemical structure(s):
Canonical SMILES:	C[C@@H]1[C@@H]2[C@@H]([C@@H](C)O)C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O
Isomeric SMILES:	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O
InChI:	InChI=1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1
InChI Key:	GXXLUDOKHXEFBQ-YJFSRANCSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/9800194

External links:
Guide to Pharmacology:	tebipenem pivoxil
Main Source:	https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Phase+III+dose+selection+for+tebipenem&id=2173&L=0&x=0&y=0&tx_solr%5Bfilter%5D%5B0%5D=main_filter_eccmid%253Atrue
Citation:	https://pubmed.ncbi.nlm.nih.gov/19673353/